Loading…
CareDx, Inc. is projected to rise to $36.72 by 2027, a +29% move from its current price of $28.51. CDNA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $27.68 | $28.51 | $29.35 | -0.01% |
| Jul 14 | $27.35 | $28.50 | $29.70 | -0.03% |
| Jul 15 | $27.09 | $28.50 | $29.98 | -0.04% |
| Jul 16 | $26.88 | $28.49 | $30.21 | -0.06% |
| Jul 17 | $26.69 | $28.49 | $30.41 | -0.07% |
| Jul 18 | $26.52 | $28.49 | $30.60 | -0.09% |
| Jul 19 | $26.36 | $28.48 | $30.77 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.36 | $28.48 | $30.77 | -0.10% |
| Week 2 | $25.50 | $28.45 | $31.74 | -0.20% |
| Week 3 | $24.86 | $28.42 | $32.50 | -0.30% |
| Week 4 | $24.33 | $28.39 | $33.15 | -0.40% |
| Week 5 | $23.86 | $28.37 | $33.72 | -0.51% |
| Week 6 | $23.45 | $28.34 | $34.25 | -0.61% |
| Week 7 | $23.07 | $28.31 | $34.74 | -0.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CareDx, Inc. is a healthcare company focused on improving outcomes for transplant patients and advancing organ health. It offers a broad portfolio of diagnostic and monitoring solutions, including AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, and AlloMap Heart, a gene expression profiling solution for heart transplant patients.
It also provides AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
The company further offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic Syndromes. In addition, it provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence-specific primer technology; and Ottr, a transplant patient management software.
Further, CareDx offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies.
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
CareDx, Inc. (CDNA) is a healthcare company whose current price is $28.82 per share, with a market cap of $1.49B and a rank of 2254. The price outlook is upturned over the forecast horizon, starting with a 2026 average equal to the current price at $28.82 and rising in subsequent years to a 2027 average of $36.16, a 2030 average of $61.86, a 2040 average of $192.15, and a 2050 average of $427.70.
The forecast also shows bullish sentiment in later years, with ROI percentages climbing from 25.5% in 2027 to 114.7% in 2030, 566.7% in 2040, and 1384% in 2050.
A major floor 43.7% below — a decisive break under it would weaken the trend.
The nearest floor, 23.0% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 18.9% above — clearing it would confirm fresh momentum.
Key CDNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CDNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.51 | Buy | $28.54 | Sell |
| MA 10 | $28.76 | Sell | $28.19 | Buy |
| MA 20 | $26.82 | Buy | $27.01 | Buy |
| MA 50 | $23.69 | Buy | $24.43 | Buy |
| MA 100 | $21.10 | Buy | $22.29 | Buy |
| MA 200 | $19.34 | Buy | $20.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.87 | Neutral |
| Stoch RSI (14) | 14.17 | Buy |
| CCI (20) | 54.38 | Neutral |
| Williams %R (14) | -18.20 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | 13.50 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 81.80 | Sell |
| TRIX (15) | 1.02 | Buy |
| Awesome (5,34) | 3.52 | Buy |
| Ultimate (7,14,28) | 55.09 | Neutral |
| Momentum (10) | 0.66 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 28.24 | Buy |
| ADX (14) | 29.66 | Buy |
| ATR (14) | 0.73 | Info |
The 30-day technical picture is bullish, with RSI14 at 70. This indicates positive near-term momentum. The stock trades above both key moving averages, with SMA50 at $22.13 and SMA200 at $18.60, signaling an upward drift.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.05 | $28.51 | $35.70 | 0% | Neutral | |
| $29.04 | $36.72 | $49.25 | +29% | Bullish | |
| $30.51 | $39.76 | $55.45 | +39% | Bullish | |
| $34.81 | $46.51 | $66.88 | +63% | Bullish | |
| $47.42 | $64.77 | $95.55 | +127% | Bullish | |
| $56.08 | $78.17 | $117.93 | +174% | Bullish | |
| $64.72 | $91.92 | $141.49 | +222% | Bullish | |
| $69.64 | $100.67 | $157.79 | +253% | Bullish | |
| $70.50 | $103.64 | $165.18 | +264% | Bullish | |
| $80.90 | $120.86 | $195.62 | +324% | Bullish | |
| $137.70 | $221.39 | $382.31 | +677% | Bullish | |
| $265.98 | $485.80 | $921.61 | +16.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.05 | $28.51 | $33.70 | +0.00% |
| August 2026 | $23.34 | $27.60 | $33.57 | -3.18% |
| September 2026 | $23.61 | $28.14 | $34.62 | +1.93% |
| October 2026 | $23.75 | $28.49 | $35.41 | +1.25% |
| November 2026 | $23.15 | $27.91 | $34.98 | -2.02% |
| December 2026 | $23.32 | $28.27 | $35.70 | +1.27% |
Click any year to see its month-by-month CDNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CDNA price prediction for 2026 points to an average of $28.51 (low $16.05, high $35.70) — a potential gain of 0% on today's $28.51. A consolidation phase looks the most probable path here.
In 2027, CDNA is projected to trade between $29.04 and $49.25, averaging $36.72 — a potential gain of +29% from today's $28.51. That is up +29% on the projected 2026 average. Momentum favours further upside here.
CareDx, Inc.'s 2028 outlook centres on $39.76, within a $30.51 to $55.45 range. That is up +8% on the projected 2027 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CDNA could reach as high as $66.88, with a base case around $46.51 and support toward $34.81 — roughly +63% from $28.51. Momentum favours further upside here.
Expect CDNA to range from $47.42 to $95.55 through 2030. The $64.77 average target implies a +127% move from current prices. That is up +39% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CDNA price prediction for 2031 points to an average of $78.17 (low $56.08, high $117.93) — a potential gain of +174% on today's $28.51. Momentum favours further upside here.
In 2032, CDNA is projected to trade between $64.72 and $141.49, averaging $91.92 — a potential gain of +222% from today's $28.51. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
CareDx, Inc.'s 2033 outlook centres on $100.67, within a $69.64 to $157.79 range. That is up +10% on the projected 2032 average. That marks a +253% change versus current levels. Momentum favours further upside here.
By 2034, CDNA could reach as high as $165.18, with a base case around $103.64 and support toward $70.50 — roughly +264% from $28.51. Buyers look set to stay in control over this stretch.
Expect CDNA to range from $80.90 to $195.62 through 2035. The $120.86 average target implies a +324% move from current prices. That is up +17% on the projected 2034 average. Momentum favours further upside here.
The CDNA price prediction for 2040 points to an average of $221.39 (low $137.70, high $382.31) — a potential gain of +677% on today's $28.51. Buyers look set to stay in control over this stretch.
In 2050, CDNA is projected to trade between $265.98 and $921.61, averaging $485.80 — a potential gain of +16.0x from today's $28.51. That is up +119% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CDNA today (≈ 35.075412 CDNA) could be worth
$17,039.54
+$16,039.54 (+1604%) by 2050 · US Dollar
Based on the average projected CDNA price of $485.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CDNAwould be worth at today's price.
$1,000 invested in CDNA on Jul 10, 2025 (≈ 48.473099 CDNA) would be worth
$1,381.97
+$381.97 (+38.2%) today · 1.38× · US Dollar
Based on a CDNA entry price of $20.63 vs. today's $28.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.19 | $976.7 | -2.3% |
| 1 month ago | $23.46 | $1,215.26 | +21.5% |
| 3 months ago | $16.05 | $1,776.32 | +77.6% |
| 6 months ago | $20.57 | $1,386 | +38.6% |
| 1 year ago | $20.63 | $1,381.97 | +38.2% |
| All time (5.0y) ago | $83.28 | $342.34 | -65.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CDNA forecast.
Our base-case forecast reaches $57.00 around 2030.
Implied market cap at $57.00: $2.94B
Across the multi-year horizon, the forecast paints a bullish path. The 2030 average price is $61.86 with a ROI of 114.7% and a bullish sentiment, followed by a 2040 average of $192.15 with a ROI of 566.7% and a bullish sentiment, and a 2050 average of $427.70 with a ROI of 1384% and a bullish sentiment. These figures illustrate a sustained uptrend in the outlook, though they are estimates and not guarantees.
The path hinges on factors that can influence market conditions, regulatory dynamics, and company performance.
Tap a question to reveal the answer.
2030 avg $61.86; min $44.09; max $94.00; ROI 114.7%; sentiment bullish.
The forecast shows bullish sentiment from 2027 onward with rising averages and positive ROI, ranging from 25.5% in 2027 to 1384% in 2050.
Yes, the 2040 max price is $346.75 and the 2040 avg is $192.15; the 2035 max is $186.31, so the 2040 forecast max exceeds $200.
Current price $28.82; market cap $1.49B.
30-day range is $23.16 to $35.87; RSI14 is 70.
CareDx, Inc. Community Discussion
0Share your CareDx, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.